These abnormal post-translational modifications not only provide a molecular biological basis for the targets and clinical efficacy of SSRIs but also lay a solid theoretical foundation for comprehensively understanding the functional regulation of SERT and its pathophysiological roles and therapeutic strategies in psychiatric disorders such as obsessive-compulsive disorder, depression, autism, and schizophrenia. The gene discussed is SLC6A4; the disease is autism.